Faculty

• Ravi Allada, MD, Northwestern University
• Rich Baron, MD American Board of Internal Medicine and the ABIM Foundation
• Anders Carlson, MD, International Diabetes Center
• Alta DeRoo, MD, DFASAM, FACOG Hazelden Betty Ford Foundation
• Laura Esserman, MD, MBA UCSF
• Stephanie Faubion, MD, MBA, Mayo Clinic
• Kelly Grosklags, LICSW, BCD, FAAGC, FT, Conversations with Kelly
• Richard Isaacson, MD Institute for Neurodegenerative Diseases
• Prakash Jayakumar, MD, PhD, The University of Texas at Austin, Dell Medical School
• Roy Kao, MD, University of Minnesota Medical School
• Matthew O'Connor, MD, Children’s Hospital of Philadelphia
• Bryan Piatt, Mental Health Advocate
• Melissa Roberts, MSN, RN, UW Health Transplant Center
• Lisa Sanders, MD, FACP, Yale School of Medicine
• Retu Saxena, MD, FACC, Allina Health Minneapolis Heart Institute

Planners
Elizabeth Albert, MD
Clinical Activity Manager
Optum Health Education

Rebecca Gleason, RN, CCM
Activity Manager
Optum Health Education

Lisa Latts, MD, MSPH, MBA, FACP
Senior Medical Director, Value-Based Care
Optum

Jennifer Malin, MD, PhD
Senior Vice President, Clinical Value
Optum Health
Chief Medical Officer
Optum Health Solutions

Tina Rydland, PharmD
Executive Pharmacy Consultant

Crystal Wong, MD
President
Propoint Medical Writing

Disclosures of relevant financial relationships
In accordance with the Accreditation Council for Continuing Medical Education's (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, OptumHealth Education (OHE) requires all those in control of educational content to disclose their financial relationships with ineligible companies within the prior 24 months. Ineligible companies are defined by the ACCME as companies whose primary business is producing, marketing, selling, re-selling, or distributing health care products used by or on patients. Individuals must disclose all financial relationships, regardless of the amount, with ineligible companies and regardless of their view of the relevance of the relationship to the education. OHE ensures that the content is independent of commercial bias.

• Anders L. Carlson, MD: Abbott Diabetes Care, Dexcom, Insulet, Tandem Diabetes, UnitedHealth Inc. (Clinical Research Investigator); MannKind (Consulting/Advisory Board); Eli Lilly, Medtronic/Companion Medical, Novo Nordisk, Sanofi  (Clinical Research Investigator & Consulting/Advisory Board)
• Laura Esserman, MD, MBA: Moderna (Grant/Research Support); Blue Cross/Blue Shield (Advisory Board)
• Richard Isaacson, MD: Novo Nordisk, Eli Lilly (A); Acadia, Retain Health (C) 
• Prakash Jayakumar, MD, PhD: Ora Medical (Consultant) (Stocks and Other Ownership Interests)
• Roy Kao, MD: Editas, Vertex (Grant/Research Support)
• Orvin Visaya, MD: Fresenius (A); Evergreen Nephrology (A, I) 

All relevant financial relationships have been mitigated. 

The remaining faculty and planners have no financial relationships to disclose.